Top Markets
Coin of the day
Healios K.K. Healios K.K.

Healios K.K.

4593
株式のランク #17173
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011,... Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
株価
$1.89
時価総額
$254.55M
変化(1日)
-2.03%
変化(1年)
-48.53%
JP
取引 Healios K.K. (4593)

カテゴリー

Healios K.K.(4593)のP/B比率
2026 時点のP/B比率 TTM: 0
Healios K.K. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Healios K.K. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH